Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 704289, 8 pages
http://dx.doi.org/10.1155/2014/704289
Clinical Study

Long-Term Effects and Prognosis in Acute Heart Failure Treated with Tolvaptan: The AVCMA Trial

1Department of Cardiology and Hematology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan
2Department of Cardiology, Ohara Medical Center, Fukushima 960-0195, Japan
3Second Department of Medicine, Shirakawa Kosei General Hospital, Shirakawa 961-0005, Japan
4Department of Cardiology, Fukushima Red Cross Hospital, Fukushima 960-8530, Japan
5First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata 990-9585, Japan

Received 13 May 2014; Revised 28 August 2014; Accepted 8 September 2014; Published 10 November 2014

Academic Editor: James Kirkpatrick

Copyright © 2014 Satoshi Suzuki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [7 citations]

The following is the list of published articles that have cited the current article.

  • Tomomi Kogiso, Katsutoshi Tokushige, Etsuko Hashimoto, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, and Keiko Shiratori, “Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis,” Hepatology Research, 2015. View at Publisher · View at Google Scholar
  • Akiomi Yoshihisa, and Yasuchika Takeishi, “Heart Disease and the Liver: Interactions Between the Heart and the Liver,” The Liver in Systemic Diseases, pp. 179–202, 2016. View at Publisher · View at Google Scholar
  • Tomomi Kogiso, Kuniko Yamamoto, Mutsuki Kobayashi, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Etsuko Hashimoto, and Katsutoshi Tokushige, “Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites,” Hepatology Research, 2016. View at Publisher · View at Google Scholar
  • Takuya Iwamoto, Takuro Hisanaga, Issei Saeki, Koichi Fujisawa, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida, Masaki Maeda, Toshihiko Matsumoto, and Isao Hidaka, “Predictors of the effect of tolvaptan on the prognosis of cirrhosis,” Internal Medicine, vol. 55, no. 20, pp. 2911–2916, 2016. View at Publisher · View at Google Scholar
  • Mari Katsumata, Nobuhito Hirawa, Koichiro Sumida, Minako Kagimoto, Yosuke Ehara, Yuki Okuyama, Megumi Fujita, Akira Fujiwara, Mayumi Kobayashi, Yusuke Kobayashi, Yuichiro Yamamoto, Sanae Saka, Keisuke Yatsu, Tetsuya Fujikawa, Yoshiyuki Toya, Gen Yasuda, Kouichi Tamura, and Satoshi Umemura, “Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure,” Clinical and Experimental Nephrology, 2017. View at Publisher · View at Google Scholar
  • Tomomi Kogiso, Kuniko Yamamoto, Mutsuki Kobayashi, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Etsuko Hashimoto, and Katsutoshi Tokushige, “Predictors of the Response to Tolvaptan Therapy and Its Effect on Prognosis in Cirrhotic Patients with Ascites,” Ascites - Physiopathology, Treatment, Complications and Prognosis, 2017. View at Publisher · View at Google Scholar
  • Satoshi Suzuki, and Yasuchika Takeishi, “Molecular mechanisms and clinical features of heart failure,” Fukushima Journal Of Medical Science, 2018. View at Publisher · View at Google Scholar